# A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

> **NCT04771000** · PHASE2 · TERMINATED · sponsor: **Noorik Biopharmaceuticals AG** · enrollment: 88 (actual)

## Conditions studied

- Covid19
- Hypoxemia

## Interventions

- **DRUG:** Ambrisentan
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04771000
- **Lead sponsor:** Noorik Biopharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-08
- **Primary completion:** 2023-02-27
- **Final completion:** 2023-02-27
- **Target enrollment:** 88 (ACTUAL)
- **Why stopped:** Lack of recruitment
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04771000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04771000, "A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04771000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*